Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology

Condition(s) studied

Investigational drug(s) / intervention(s)

Analysis of biological samples: The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization: * hot spot on DNa (ddPCR/Sanger) * fusion genes on RNA (target resequencing) * Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10% * Tumor type-associated gene sequence analysis by Sanger sequencing and NGS

Study summary

Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region.

In order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future.

This will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.

Eligibility

Primary outcome measure(s)

• Average sample delivery time and % of accepted sample — After 5 year from the beginning of the study
  average sample delivery time and % of samples accepted within 48 ±12 hours of collection out of total samples sent
• Appropriateness sample labelling — After 5 year from the beginning of the study
  % samples correctly labelled according to IATA criteria out of total samples accepted within 48 hours
• Percentage of sample suitable for RNA extraction — After 5 year from the beginning of the study
  % samples suitable for RNA extraction out of total samples intended for RNA analysis
• Quantity and quality of extracted material. — After 5 year from the beginning of the study
  % of samples valid for analysis in terms of quantity of extracted material (25 ng/ul for cfDNA, 25 ng per amplicon for genomic DNA, 100 ng tot for NGS) and quality, assessed as A260/280 ratio analysis (1.8-2 per DNA).
• Research report production time — After 5 year from the beginning of the study
  research report production time (from 2 weeks for known mutation analysis to 6 months for NGS).

Trial sites (3)

More Meyer Children's Hospital IRCCS trials in Italy

Other trials for the same condition